Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tenofovir Alafenamide · Vemlidy, TAF

Small molecule · Inhibitor of HBV reverse transcriptase · developed by Gilead Sciences

Approved FDA, Nov 2016
2 Registered trials

What is Tenofovir Alafenamide?

Tenofovir alafenamide is a lipophilic phosphonamidate prodrug of tenofovir, a nucleoside reverse transcriptase inhibitor. After hepatocyte uptake and conversion to tenofovir diphosphate, it is incorporated into viral DNA and terminates chain elongation, inhibiting hepatitis B virus replication. It is studied in chronic hepatitis B.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vemlidy, TAF, GS-7340
Drug type
Small molecule
Targets
HBV reverse transcriptase, HIV-1 reverse transcriptase (secondary target)
Mechanism
Inhibitor of HBV reverse transcriptase
Pathways
viral DNA chain termination, HBV replication inhibition, HIV replication impairment
Therapy area
Infectious disease
Developer
Gilead Sciences Inc
In trials of
LGND, VIR
FDA status
Approved as Vemlidy (November 10, 2016), NDA208464 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 14, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04891770 Phase 2 Chronic Hepatitis B Completed VIR
NCT04629976 Phase 1 Chronic Hepatitis B Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis B

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.